A few years ago on this blog, I wrote several times about a small company called Zafgen (ZFGN) and their unusual epoxide-based chemical matter (beloranib) that was in development for the rare Prader-Willi syndrome. That's a genetic disorder that includes, among many other problems, constant hunger (with the complications that you'd expect from that). Zafgen was pursuing inhibitors of the enzyme methionine aminopeptidase 2 (MetAP2) as a treatment, and thus their epoxide compound. Unfortunately, the company had a death in their Phase III trial, and the confusion and consternation about that hadn't